DRUG DES DEV THER 润色咨询

Drug Design Development and Therapy

出版年份:2007 年文章数:2918 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:2.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2024-07-25 148817e2m02暂无昵称 来自江苏省

    偏重的研究方向:药物;药物治疗
    经验分享:大家好,请问大家1A1状态一般持续多久呀

    5

    展开5条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2025-05-20 匿名用户

    拒稿说不收bib这种文章类型

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2025-03-31 ms8000000453181943 来自北京

    偏重的研究方向:网药;中药
    经验分享:修回后编辑做决定都半个多月了正常吗

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2022-02-16 审稿人爸爸求求您

    1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的

    10

    展开10条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2023-09-20 41982559 来自广东省

    偏重的研究方向:药理
    经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。

    4

    展开4条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2024-08-17 ms9000001638905587 来自吉林省

    请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2024-08-31 汉库克 来自湖北省

    偏重的研究方向:治疗;药物;药物治疗
    经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2024-08-16 ms5000001216482403 来自山东省

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2024-06-19 ms5000000946930121 来自天津

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:药理
    经验分享:
    3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程
    6 March 2024

    Submission created

    20 March 2024

    Compliance checks completed

    21 March 2024

    Awaiting evaluation

    25 March 2024

    Compliance checks completed

    27 March 2024

    Awaiting evaluation

    28 March 2024

    Compliance checks completed

    2 April 2024

    Awaiting re-submission

    2 April 2024

    Revised submission received

    3 April 2024

    Editorial checks completed moved to Compliance checks

    20 March 2024

    Peer review selection

    9 April 2024

    Peer review invitations sent

    13 April 2024

    First peer reviewer allocated

    26 April 2024

    First report returned

    3 May 2024

    Second or more peer reviewer reports returned

    Editorial decision - revisions
    3 May 2024

    Report sent to the Editor-in-Chief

    4 May 2024

    Report: revise with changes

    14 May 2024

    Resubmission pending

    1 June 2024

    Resubmitted manuscript received

    5 June 2024

    Processing revised manuscript

    7 June 2024

    Sent to Editor-in-Chief for acceptance or rejection

    5 June 2024

    Query regarding revised manuscript

    Invoicing
    8 June 2024

    Invoice to follow for article processing charge subject to final decision

    10 June 2024

    Accepted for publication, invoice sent

    6

    展开6条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向:药物;药物治疗<br>经验分享:大家好,请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向:网药;中药<br>经验分享:修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天,原始数据文件太大,上传不了,大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向:药理<br>经验分享:请问大家除了wb外,是否需要上传试剂盒等数据吗?我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次,我又有一篇文章,再投的话会不会受到偏见,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向:治疗;药物;药物治疗<br>经验分享:老师们,faers数据挖掘接受吗?faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2.27投稿,7.16接受,8.15见刊。审稿慢一点,接收后速度快,还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:药理<br>经验分享:<br>3.6投稿,细胞实验文,后期补材料啥的,差不多3周之后正式进入流程<br>6 March 2024<br><br>Submission created<br><br>20 March 2024<br><br>Compliance checks completed<br><br>21 March 2024<br><br>Awaiting evaluation<br><br>25 March 2024<br><br>Compliance checks completed<br><br>27 March 2024<br><br>Awaiting evaluation<br><br>28 March 2024<br><br>Compliance checks completed<br><br>2 April 2024<br><br>Awaiting re-submission<br><br>2 April 2024<br><br>Revised submission received<br><br>3 April 2024<br><br>Editorial checks completed moved to Compliance checks<br><br>20 March 2024<br><br>Peer review selection<br><br>9 April 2024<br><br>Peer review invitations sent<br><br>13 April 2024<br><br>First peer reviewer allocated<br><br>26 April 2024<br><br>First report returned<br><br>3 May 2024<br><br>Second or more peer reviewer reports returned<br><br>Editorial decision - revisions <br>3 May 2024<br><br>Report sent to the Editor-in-Chief<br><br>4 May 2024<br><br>Report: revise with changes<br><br>14 May 2024<br><br>Resubmission pending<br><br>1 June 2024<br><br>Resubmitted manuscript received<br><br>5 June 2024<br><br>Processing revised manuscript<br><br>7 June 2024<br><br>Sent to Editor-in-Chief for acceptance or rejection<br><br>5 June 2024<br><br>Query regarding revised manuscript<br><br>Invoicing <br>8 June 2024<br><br>Invoice to follow for article processing charge subject to final decision<br><br>10 June 2024<br><br>Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152655, encodeId=b2002152655d4, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:纳米载体;中药药理<br>经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右<br>16 April 2023 Submission created<br>19 April 2023 Submission submitted + Editorial checks<br>1 May 2023 Editorial checks completed moved to Compliance checks<br>5 May 2023 Peer review selection<br>17 May 2023 Peer review invitations sent<br>31 May 2023 First peer reviewer allocated<br>1 June 2023 Two or more peer reviewers allocated<br>1 June 2023 First report returned<br>14 June 2023 Second or more peer reviewer reports returned<br>15 June 2023 Report sent to the Editor-in-Chief<br>17 June 2023 Report: revise with changes<br>29 June 2023 Resubmission pending<br>19 July 2023 Resubmitted manuscript received<br>27 July 2023 Processing revised manuscript<br>4 August 2023 Sent to Editor-in-Chief for acceptance or rejection<br>4 August 2023 Peer reviewer(s) second round<br>12 August 2023 Peer reviewer(s) second round completed<br>12 August 2023 Invoice to follow for article processing charge subject to final decision<br>14 August 2023 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b31d6477968, createdName=ms8000001566471502, createdTime=Mon Aug 14 10:18:50 CST 2023, time=2023-08-14, status=1, ipAttribution=山东省)]
    2023-08-14 ms8000001566471502 来自山东省

    审稿速度:6.0 | 投稿命中率:75.0
    偏重的研究方向:纳米载体;中药药理
    经验分享:今天接收啦,发个时间给大家看一下,总共4个月左右
    16 April 2023 Submission created
    19 April 2023 Submission submitted + Editorial checks
    1 May 2023 Editorial checks completed moved to Compliance checks
    5 May 2023 Peer review selection
    17 May 2023 Peer review invitations sent
    31 May 2023 First peer reviewer allocated
    1 June 2023 Two or more peer reviewers allocated
    1 June 2023 First report returned
    14 June 2023 Second or more peer reviewer reports returned
    15 June 2023 Report sent to the Editor-in-Chief
    17 June 2023 Report: revise with changes
    29 June 2023 Resubmission pending
    19 July 2023 Resubmitted manuscript received
    27 July 2023 Processing revised manuscript
    4 August 2023 Sent to Editor-in-Chief for acceptance or rejection
    4 August 2023 Peer reviewer(s) second round
    12 August 2023 Peer reviewer(s) second round completed
    12 August 2023 Invoice to follow for article processing charge subject to final decision
    14 August 2023 Accepted for publication, invoice sent

    7

    展开7条回复
共429条页码: 1/43页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分